Longitude Capital has closed a second fund that will focus on de-risked investment opportunities in biotech and medtech, a strategy the firm said was successful enough for its first fund to lure back existing LPs.

The oversubscribed Longitude Venture Partners II closed last week at $385 million, eclipsing the $325 million that was both the second fund's initial target and the size of the 2008 fund LVP I.